NPS RADAR provides health professionals with timely, independent evidence-based information on new drugs and medical tests and changes to listings on the Pharmaceutical Benefits Scheme.

NPS RADAR is print-published 3 times a year, in line with major updates to the Schedule of Pharmaceutical Benefits, so it is available around the time when new medicines can be prescribed or dispensed.

Our free NPS RADAR email alerts keep subscribers up to date with new drugs and medical tests as each new issue of NPS RADAR is released.

Latest issue

Indacaterol with glycopyrronium (Ultibro Breezhaler) for chronic obstructive pulmonary disease

Indacaterol 110 micrograms / glycopyrronium 50 micrograms (Ultibro Breezhaler 110/50) is a fixed-dose combination for providing maintenance bronchodilation for 24 hours after a once-daily dose in patients with chronic obstructive pulmonary disease. The long-acting beta-2 agonist / long-acting muscarinic antagonist combination bronchodilator provides a single-inhaler alternative to a LABA and LAMA in two separate inhaler devices.

Brief item: Varenicline (Champix) for smoking cessation – changed note to restriction

From 1 October 2014 the note to the PBS listing for varenicline tartrate has changed to permit another course of varenicline (instead of buproprion) in patients who did not stop smoking after an initial 12- or 24-week treatment course, provided that 6 months have elapsed between starting the previous course of varenicline and the subsequent course.